TLR4 and cancer: The EV-based anticancer vaccine nanoparticle HDEA@EVAT was designed and developed by conjugating pH-sensitive DEAP, CD44 receptor-bound polysaccharide HA, TLR4-associated MPLA, and cancer-involved antigen MUC1.